Table 1.

Demographics, clinical characteristics, and treatment outcomes of the patients with M. romeroi eumycetoma cases in the literature.

Demographics				Clinical Characteristics				Diagnosis		Treatment	Outcome	Reference
Age (Years)	Sex	Country of Occurrence	Country of Origin	Site	Pain	Bone Involvement	Pre-Treatment Period (Months)	Histology & Culture	Molecular Identification
63	F	Somalia	-	NA	NA	NA	18	Yes	No	Surgery	NA	[11] *
39	M	Cambodia	-	Foot	Yes	Yes	21	Yes	No	Excision	Recurrence	[4]
NA	M	Senegal	-	Leg	NA	NA	NA	Yes	No	NA	NA	[5]
NA	M			Sole
NA	M			Hand
53	M	France	-	Foot	Yes	Yes	24	Yes	No	Amputation	NA	[6]
NA	NA	Venezuela	-	NA	NA	NA	NA	Yes	No	NA	NA	[7]
37	M	India	India	Foot, ankle	No	NS	216	Yes	No	NA	NA	[8]
42	M			Foot	No	Yes	60	Yes	No
30	F	NA	NA	Foot, leg	NA	Yes	180	Yes	No	KTC (400 mg/d) for 8 months	Great improvement without further recorded follow-up	[12] **
42	M	Brazil	-	Sole	NA	No	36	Yes	No	KTC	Failure	[9]
										ITC	Slight improvement
36	M	India	-	Foot	NA	NA	NA	Yes	No	NA	NA	[10]
56	M	UK	Pakistan	Foot	Yes	Yes	204	Yes	Yes	ITC 200 mg b.i.d + 5FC 1000 mg t.i.d for 9 months	Failure	[13]
										VRC 200 mg b.i.d for 7 weeks, then 150 mg b.i.d for 4 years	Minimal improvement
										POS 400 mg t.i.d for 17 months	Decrease in pain and swelling, then relapse
24	M	India	-	NA	NA	NA	NA	Yes	Yes	AMB and surgery	Recurrence	[14] ***

Abbreviations: AMB: Amphotericin B, b.i.d: twice a day, d: day, F: female, ITC: Itraconazole, 5-FC: Flucytosine, KTC: ketoconazole, M: male, NA: not available, POS: Posaconazole, t.i.d: three times a day, VRC: Voriconazole, we: week, yr: year. * Five cases of M. romeroi mycetoma were identified in this survey on a histological basis only. Cultures were positive for M. romeroi in only one case, so the other four cases were excluded. ** A case series of 8 patients from India, Saudi Arabia, and Yemen, the origin of the patient affected by M. romeroi was not specified. *** Case series from India, the exact year of diagnosis of individual cases, was not provided.